These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 19335721)

  • 41. Safe use of vaccines and vaccine compliance with food safety requirements.
    Grein K; Papadopoulos O; Tollis M
    Rev Sci Tech; 2007 Aug; 26(2):339-50. PubMed ID: 17892156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uncertainties and anxieties about vaccination, answering parent's concerns.
    Purssell E
    J Pediatr Nurs; 2009 Oct; 24(5):433-40. PubMed ID: 19782902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Medical advice for the traveller].
    Larsen CS; Krølner BK
    Ugeskr Laeger; 2005 Oct; 167(42):3963-8. PubMed ID: 16232392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [New vaccination strategies].
    Plotkin SA
    Bull Acad Natl Med; 2008 Mar; 192(3):511-8; discussion 518-9. PubMed ID: 18819697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N; Nasar A; Suri MF; Qureshi AI
    J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Communicating the benefits and risks of vaccines.
    Kimmel SR; Wolfe RM
    J Fam Pract; 2005 Jan; 54(1 Suppl):S51-7. PubMed ID: 15623394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The Norwegian vaccination program].
    Nøkleby H; Feiring B
    Tidsskr Nor Laegeforen; 2006 Oct; 126(19):2538-40. PubMed ID: 17028636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
    Pickering LK; Baker CJ; Freed GL; Gall SA; Grogg SE; Poland GA; Rodewald LE; Schaffner W; Stinchfield P; Tan L; Zimmerman RK; Orenstein WA;
    Clin Infect Dis; 2009 Sep; 49(6):817-40. PubMed ID: 19659433
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methods of ensuring vaccine safety.
    Ball R
    Expert Rev Vaccines; 2002 Aug; 1(2):161-8. PubMed ID: 12901555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Fighting antibiotic resistance].
    Harthug S; Akselsen PE
    Tidsskr Nor Laegeforen; 2008 Oct; 128(20):2343-6. PubMed ID: 19096492
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Recent changes in the epidemiology of infectious diseases in the Netherlands: the report 'Status of infectious diseases in the Netherlands, 2000-2005'].
    Rahamat-Langendoen JC; van Vliet JA
    Ned Tijdschr Geneeskd; 2007 Jun; 151(24):1333-8. PubMed ID: 17665624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Routine and recommended vaccinations for travellers.
    Duszczyk E; Talarek E
    Int Marit Health; 2008; 59(1-4):116-23. PubMed ID: 19227745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice.
    Nicolas JF; Guy B
    Expert Rev Vaccines; 2008 Oct; 7(8):1201-14. PubMed ID: 18844594
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Communicating vaccine safety to the media and general public.
    Oubari H; Tuttle R; Rath B; Bravo L
    Curr Drug Saf; 2015; 10(1):80-6. PubMed ID: 25859680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Imported diseases: information, communication and continuing education].
    Degrémont A
    Ther Umsch; 1990 Oct; 47(10):839-43. PubMed ID: 2260025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Which pharmacovigilance for vaccines?
    Le Louët H; Loupi E; Haramburu F;
    Therapie; 2007; 62(3):241-7. PubMed ID: 17803893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Scientists worry about some risks more than the public.
    Scheufele DA; Corley EA; Dunwoody S; Shih TJ; Hillback E; Guston DH
    Nat Nanotechnol; 2007 Dec; 2(12):732-4. PubMed ID: 18654416
    [No Abstract]   [Full Text] [Related]  

  • 59. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
    Patel MM; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulations and procedures in parasite vaccine development.
    Schetters TP; Gravendyck M
    Parasitology; 2006; 133 Suppl():S189-95. PubMed ID: 17274846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.